IOVA stock gains as Piper sees approval for melanoma therapy this year (NASDAQ:IOVA)

Wall street sign in New York with New York Stock Exchange background

naphtalina/iStock via Getty Images

Iovance Biotherapeutics (NASDAQ:IOVA) added ~8% in the morning hours Friday as Piper Sandler upgraded the clinical-stage biotech to Overweight from Neutral, citing potential FDA approval for its lead asset lifileucel in melanoma later this year.

The analystIOVA

Source link

5 Trading strategies to make money

Looking to boost your trading profits?

Get you copy of our FREE Ebook Now !!!